Harel, Tamar;
Spicher, Camille;
Scheer, Elisabeth;
Buchan, Jillian G;
Cech, Jennifer;
Folland, Chiara;
Frey, Tanja;
... Tora, László; + view all
(2024)
De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features.
Brain
, Article awae160. 10.1093/brain/awae160.
(In press).
![[thumbnail of awae160.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
awae160.pdf - Accepted Version Access restricted to UCL open access staff until 17 May 2025. Download (1MB) |
Abstract
Deubiquitination is critical for the proper functioning of numerous biological pathways such as DNA repair, cell cycle progression, transcription, signal transduction, and autophagy. Accordingly, pathogenic variants in deubiquitinating enzymes (DUBs) have been implicated in neurodevelopmental disorders (ND) and congenital abnormalities. ATXN7L3 is a component of the DUB module of the SAGA complex, and two other related DUB modules, and serves as an obligate adaptor protein of 3 ubiquitin-specific proteases (USP22, USP27X or USP51). Through exome sequencing and GeneMatching, we identified nine individuals with heterozygous variants in ATXN7L3. The core phenotype included global motor and language developmental delay, hypotonia, and distinctive facial characteristics including hypertelorism, epicanthal folds, blepharoptosis, a small nose and mouth, and low-set posteriorly rotated ears. In order to assess pathogenicity, we investigated the effects of a recurrent nonsense variant [c.340C>T; p.(Arg114Ter)] in fibroblasts of an affected individual. ATXN7L3 protein levels were reduced, and deubiquitylation was impaired, as indicated by an increase in histone H2Bub1 levels. This is consistent with the previous observation of increased H2Bub1 levels in Atxn7l3-null mouse embryos, which have developmental delay and embryonic lethality. In conclusion, we present clinical information and biochemical characterization supporting ATXN7L3 variants in the pathogenesis of a rare syndromic ND.
Archive Staff Only
 |
View Item |
